List of Excipients in Branded Drug ROXYBOND

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	ALGINIC ACID
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	AMMONIA
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	BUTYL ALCOHOL
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	CELLULOSE, MICROCRYSTALLINE

RoxyBond Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

RoxyBond is an immediate-release oxycodone hydrochloride tablet with FDA-recognized abuse-deterrent properties. Its commercial value depends on a tightly controlled excipient system that supports tablet hardness, rapid therapeutic disintegration, resistance to crushing, and difficult manipulation for non-oral abuse. The strongest opportunities are in abuse-deterrent generic development, high-performance excipients, contract manufacturing, analytical testing, and reformulation platforms for other immediate-release opioids.

What is RoxyBond and how does its formulation work?

RoxyBond is an immediate-release oral tablet containing oxycodone hydrochloride in 5 mg, 15 mg, and 30 mg strengths. Purdue Pharma received FDA approval in April 2017 under NDA 209777.[1]

The product uses an abuse-deterrent formulation rather than extended release. Its design addresses manipulation methods such as crushing, pulverizing, dissolving, and preparation for insufflation or injection. The FDA classifies the product as having abuse-deterrent properties based on laboratory and human abuse-potential studies, but the labeling states that no opioid formulation prevents all abuse.[1,2]

RoxyBond dosage forms and formulation objectives

Attribute	RoxyBond profile
Active ingredient	Oxycodone hydrochloride
Dosage form	Immediate-release tablet
Strengths	5 mg, 15 mg, 30 mg
FDA approval	April 2017
NDA	209777
Therapeutic area	Acute and chronic pain requiring an opioid analgesic
Abuse-deterrent objective	Resistance to crushing and manipulation; reduced suitability for non-oral administration
Regulatory pathway	New drug application with abuse-deterrent labeling
Drug class	Schedule II opioid

The formulation must balance two opposing requirements. It must be hard and mechanically resistant during abuse manipulation, yet it must disintegrate sufficiently after normal oral administration to deliver immediate-release oxycodone.

What excipients are used in RoxyBond?

The FDA-approved labeling identifies the principal inactive ingredients as colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, and stearic acid.[1]

Excipient	Primary formulation role	Commercial relevance
Microcrystalline cellulose	Diluent, dry binder, compression aid	Supports tablet strength and manufacturing consistency
Crospovidone	Superdisintegrant	Helps preserve immediate-release performance
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces ejection force and tooling adhesion
Stearic acid	Lubricant and processing aid	Supports tablet manufacture and surface properties
Sodium lauryl sulfate	Wetting and dissolution aid	Helps liquid penetration and drug release

The excipient list is commercially important because RoxyBond's performance depends on the combined system, not on any one inactive ingredient. A substitute excipient may be pharmaceutically acceptable in a conventional oxycodone tablet but fail to reproduce the required mechanical and manipulation-resistance profile.

How microcrystalline cellulose supports RoxyBond performance

Microcrystalline cellulose is likely the principal structural excipient. Its plastic deformation characteristics support tablet hardness under compression. A high-strength matrix can reduce friability and make the dosage form more difficult to pulverize.

The commercial opportunity is strongest for grades that provide:

• High compactability at relatively low compression force.
• Consistent tablet tensile strength.
• Low batch-to-batch variability.
• Controlled moisture content.
• Compatibility with direct-compression manufacturing.
• Predictable performance across 5 mg, 15 mg, and 30 mg strengths.

Silicified or co-processed cellulose systems can be relevant in development because they may improve flow and compactability. Any substitution would require comparative data on hardness, friability, disintegration, dissolution, crushing behavior, and abuse-deterrence performance.

How crospovidone supports immediate release

Crospovidone provides rapid liquid uptake and tablet breakup. In an abuse-deterrent immediate-release product, the developer must avoid a formulation that becomes excessively hard or forms a stable mass that delays oral drug release.

The development risk is an over-engineered tablet that performs well in crushing tests but fails the immediate-release dissolution profile. Crospovidone grade, particle size, loading, and distribution can materially affect both normal use and manipulation behavior.

How lubricants affect product performance

Magnesium stearate and stearic acid reduce friction during compression and tablet ejection. Excessive lubrication, particularly with hydrophobic magnesium stearate, can reduce tablet tensile strength and delay wetting or dissolution.

For a RoxyBond-type product, lubricant optimization should evaluate:

• Mixing time.
• Specific surface area.
• Lubricant concentration.
• Tablet ejection force.
• Tensile strength.
• Friability.
• Disintegration.
• Dissolution after storage.
• Crushing and powder-generation behavior.

Lubrication is a high-value development variable because small processing changes can alter both manufacturability and abuse-deterrent performance.

What formulation characteristics create RoxyBond's abuse-deterrent profile?

RoxyBond's abuse-deterrent design is based on physical and chemical properties of the tablet matrix. The FDA's abuse-deterrent guidance evaluates whether manipulation becomes more difficult, less efficient, or less attractive compared with a conventional formulation.[2]

Relevant performance attributes include:

1. Resistance to crushing and grinding.
2. Limited production of fine particles.
3. Reduced ability to prepare a powder suitable for insufflation.
4. Difficulty dispersing the drug in water or other solvents.
5. Reduced syringeability of manipulated material.
6. Preservation of immediate-release oral delivery.
7. Acceptable stability through the labeled shelf life.

A commercial developer should not treat tablet hardness as a standalone surrogate for abuse deterrence. A harder tablet may still produce an injectable dispersion or a usable insufflation powder. The complete package requires mechanical, particle-size, extraction, dissolution, syringeability, and human abuse-potential evidence.

Which analytical tests matter most?

A RoxyBond-type development program should include:

Test category	Key measurements
Mechanical resistance	Crushing force, tensile strength, friability, milling energy
Powder behavior	Particle-size distribution, respirable fraction, morphology
Extraction	Oxycodone recovery in water, alcohol, and other relevant solvents
Injectability	Viscosity, filtration, syringeability, needle passage
Release	Immediate-release dissolution, disintegration, drug release profile
Stability	Assay, impurities, hardness, dissolution, moisture sensitivity
Manufacturing	Blend uniformity, content uniformity, compression robustness

The commercial value of specialized test methods is significant. Generic developers and excipient suppliers need methods that correlate laboratory performance with FDA expectations without relying on proprietary sponsor data.

What commercial opportunities exist for RoxyBond excipients?

1. Abuse-deterrent generic oxycodone

The largest opportunity is a generic or follow-on immediate-release abuse-deterrent oxycodone product. A successful applicant would need to address both pharmaceutical equivalence and the abuse-deterrent performance described in the reference product's labeling and FDA guidance.

A conventional oxycodone generic would not automatically be substitutable for RoxyBond on the basis of active ingredient, strength, dosage form, and route alone. The abuse-deterrent formulation characteristics create additional development and regulatory requirements.

Commercial opportunities include:

• Co-processed diluent-binder systems.
• High-compactability microcrystalline cellulose.
• Low-moisture excipient grades.
• Optimized disintegrant systems.
• Lubricant packages that preserve dissolution.
• Excipient combinations designed for controlled crushing resistance.
• Drug-product development and bioequivalence support.

2. Platform technology for other opioids

An excipient system validated for RoxyBond-like performance could be adapted to other immediate-release opioids, subject to product-specific development. Potential targets include hydrocodone, morphine, oxymorphone, and combination analgesics.

The transferability of the platform depends on:

• Dose loading.
• Drug solubility.
• Salt form.
• Particle size.
• Compression behavior.
• Therapeutic dissolution requirements.
• Abuse routes relevant to the product.
• Existing patent and regulatory restrictions.

A modular platform could use a common structural matrix while adjusting disintegrant, surfactant, lubricant, and process parameters for each active ingredient.

3. Contract development and manufacturing

RoxyBond-type products require specialized formulation development and abuse-deterrence testing. Contract development organizations can monetize:

• Preformulation screening.
• Direct-compression optimization.
• Scale-up and process validation.
• Tablet manipulation testing.
• Extractability and syringeability studies.
• Stability programs.
• FDA submission support.

Manufacturers with experience in high-hardness immediate-release tablets have a competitive advantage, but they must demonstrate that stronger compression does not compromise dissolution or content uniformity.

4. Excipient supplier partnerships

Excipient suppliers can pursue preferred-supplier status by offering:

• Consistent particle-size distributions.
• Low heavy-metal and microbial risk.
• Reliable global supply.
• Regulatory documentation for multiple jurisdictions.
• Excipient-change comparability packages.
• Technical support for scale-up.
• Custom co-processed systems.

The highest-value products are unlikely to be commodity magnesium stearate or standard microcrystalline cellulose alone. Premium positioning is more likely for engineered excipient combinations with demonstrated effects on tablet strength, manipulation resistance, and immediate release.

What patent and regulatory barriers affect RoxyBond opportunities?

FDA regulatory status and Orange Book position

RoxyBond was approved as NDA 209777. Its FDA labeling identifies oxycodone hydrochloride as the active ingredient and describes abuse-deterrent characteristics.[1]

The Orange Book is the controlling public source for listed patents, exclusivity, therapeutic equivalence codes, and reference-product information.[3] Patent listings and marketing status can change through updates, litigation, delisting, expiration, or regulatory action. Commercial diligence should therefore distinguish between:

• The approved RoxyBond formulation.
• Listed patents covering the product or formulation.
• Patents covering abuse-deterrent manufacturing methods.
• Patents covering broader opioid formulations.
• Regulatory exclusivity.
• Commercial availability.

The approval in 2017 did not create new chemical-entity exclusivity for oxycodone, an established active ingredient. Any initial regulatory exclusivity would have been limited compared with an NCE product. The longer-term barrier is formulation and abuse-deterrence IP rather than oxycodone composition-of-matter protection.

Paragraph IV and generic-entry risk

A generic applicant may challenge listed patents through an ANDA Paragraph IV certification. The commercial risk depends on:

• Whether relevant formulation patents remain listed.
• The expiration dates and patent-term adjustments.
• Whether the applicant uses a non-infringing formulation.
• Whether the formulation meets FDA abuse-deterrent expectations.
• The timing of patent litigation.
• Any 30-month stay triggered by a timely infringement suit.
• Settlement provisions governing launch.

A Paragraph IV filing does not establish that a generic will launch. The applicant must still obtain FDA approval, satisfy pharmaceutical-equivalence requirements, and produce evidence supporting any proposed abuse-deterrent labeling.

Formulation and method-of-use patents

RoxyBond-related protection may involve multiple claim categories:

Claim type	Potential scope
Composition claims	Specific excipient and oxycodone combinations
Tablet claims	Hardness, density, porosity, or physical characteristics
Abuse-deterrence claims	Resistance to crushing, extraction, or syringeability
Manufacturing claims	Compression, granulation, coating, or processing conditions
Method claims	Use of the product for analgesia with abuse-deterrent properties
Analytical claims	Testing or characterization of manipulated material

Method-of-use patents are usually less important for a generic seeking conventional analgesic labeling than formulation claims. A generic may still face litigation if its product reproduces patented structural or processing elements.

How strong is the RoxyBond excipient strategy?

The strategy is technically credible but commercially demanding. Its strength comes from integration of several conventional excipients into a product-specific performance profile.

Strength	Commercial implication
Established excipient classes	Supply-chain access is generally feasible
Multiple formulation variables	Design-around opportunities exist
Immediate-release product	Large clinical use base and familiar manufacturing
Abuse-deterrent labeling	Differentiation from conventional generics
Oxycodone demand	Commercial market exists, but access is heavily controlled
Schedule II status	Distribution, compliance, and diversion controls increase cost
Product-specific testing	Higher development barrier than ordinary IR tablets

The principal vulnerability is that many excipients are standard and may be substituted. Patent strength therefore depends on the breadth and validity of claims covering the combination, tablet properties, manufacturing process, and abuse-deterrent results. A formulation built only around generic excipients may have limited freedom-to-operate protection unless the technical arrangement or process is distinctive.

How does RoxyBond compare with conventional oxycodone generics?

Factor	RoxyBond	Conventional oxycodone IR generic
Active ingredient	Oxycodone hydrochloride	Oxycodone hydrochloride
Release	Immediate	Immediate
Abuse-deterrent design	Yes	Usually no
Excipient optimization	Focused on resistance and oral release	Focused mainly on manufacturability and bioequivalence
Regulatory burden	Higher	Standard ANDA requirements
Differentiation	Abuse-deterrent labeling and formulation	Price and supply
Manufacturing complexity	Higher	Lower
Potential payer premium	Possible but uncertain	Limited
Patent exposure	Formulation and ADF patents	Conventional product patents, if any
Generic substitution	Requires product-specific assessment	More established

RoxyBond's commercial advantage is differentiation. Its disadvantage is cost. The product must justify specialized development, manufacturing, testing, compliance, and distribution controls in a market where physicians and payers may still prioritize price.

What revenue and market opportunities exist?

Public sources do not establish a reliable standalone revenue figure for RoxyBond. Commercial exposure should instead be modeled from prescription volume, net price, payer mix, supply continuity, and the degree of substitution by conventional oxycodone products.

The principal revenue scenarios are:

1. Premium branded abuse-deterrent sales in selected opioid-prescribing segments.
2. Institutional and hospital contracts requiring abuse-deterrent options.
3. Licensing of formulation or manufacturing technology.
4. Supply of differentiated excipients to multiple opioid products.
5. Generic entry using a non-infringing abuse-deterrent platform.
6. Expansion into other controlled-substance dosage forms.

The strongest near-term commercial model for excipient companies is usually a platform or supply agreement rather than reliance on one branded opioid product. That model reduces exposure to prescription restrictions, litigation, opioid-policy changes, and product-specific sales volatility.

What geographic coverage and manufacturing barriers apply?

United States commercialization is the clearest opportunity because FDA abuse-deterrent guidance and Orange Book procedures create a defined regulatory framework. International expansion requires separate analysis under national drug laws, controlled-substance rules, patent systems, and substitution standards.

Manufacturing barriers include:

• Controlled-substance handling licenses.
• Secure raw-material storage.
• Batch-level reconciliation.
• Diversion monitoring.
• Specialized compression capability.
• Validated manipulation testing.
• Excipient change control.
• Serialization and supply-chain controls.
• Regulatory documentation for each market.

European and other international markets may not use the same abuse-deterrent labeling or generic-substitution framework as the United States. The technical formulation may transfer, but the commercial claim and reimbursement strategy may not.

What generic launch scenarios exist for RoxyBond?

Scenario 1: Conventional oxycodone generic launch

A conventional generic competes on price but does not capture the abuse-deterrent positioning. It may pressure RoxyBond volume without directly replicating the formulation.

Scenario 2: Abuse-deterrent generic launch

A qualifying ADF generic could compete directly for substitution and institutional purchasing. This scenario creates the greatest pressure on RoxyBond pricing and share.

Scenario 3: Non-infringing reformulation

A developer may use different excipients or processing conditions while seeking equivalent therapeutic performance and separate abuse-deterrent evidence. This is the principal design-around pathway.

Scenario 4: Authorized or licensed generic

A branded manufacturer or licensee could distribute an authorized generic using the reference product or a closely related formulation. This could limit third-party generic economics while expanding volume.

Key Takeaways

• RoxyBond is an FDA-approved immediate-release oxycodone hydrochloride tablet with abuse-deterrent properties.
• Its listed excipients are microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, and stearic acid.
• The excipient system must deliver tablet strength and manipulation resistance without sacrificing immediate-release dissolution.
• The largest commercial opportunity is an abuse-deterrent generic or transferable formulation platform for other opioids.
• Excipient suppliers can differentiate through high-compactability binders, engineered disintegrants, lubricant systems, and co-processed blends.
• Patent risk is concentrated in formulation, tablet-property, manufacturing, and abuse-deterrence claims rather than oxycodone composition-of-matter protection.
• Paragraph IV risk depends on current Orange Book listings, patent expiration, litigation, and the ability to design around protected formulation features.
• Revenue modeling requires prescription, pricing, payer, and supply data; a standalone public RoxyBond revenue figure is not established in the cited FDA sources.
• Schedule II controls and specialized manufacturing materially raise the cost of entry.
• The most defensible commercial strategy is a multi-product excipient or formulation platform rather than dependence on RoxyBond alone.

FAQs

Can standard excipients be used to develop a RoxyBond generic?

Yes. Standard excipients may be used, but the finished product must meet the applicable pharmaceutical-equivalence, dissolution, manufacturing, and abuse-deterrent requirements. Use of the same excipients does not by itself establish equivalence.

Is RoxyBond an extended-release opioid?

No. RoxyBond is an immediate-release oxycodone tablet. Its differentiation comes from abuse-deterrent formulation properties, not extended-release drug delivery.

Which excipient is most important for RoxyBond tablet hardness?

Microcrystalline cellulose is a principal structural excipient, but tablet hardness depends on the complete formulation and compression process. Lubricant level, moisture, particle size, and compression force also affect performance.

Does an abuse-deterrent oxycodone product eliminate opioid diversion?

No. FDA abuse-deterrent labeling indicates that manipulation may be more difficult or less attractive. It does not eliminate abuse, diversion, overdose, or oral misuse.

Can a RoxyBond-type excipient platform be used for hydrocodone?

Potentially, but each active ingredient requires separate formulation development, abuse-deterrence testing, regulatory assessment, and patent analysis. Oxycodone performance cannot be assumed to transfer directly to hydrocodone.

References

1. U.S. Food and Drug Administration. (2017). RoxyBond (oxycodone hydrochloride) tablets, for oral use, CII: Prescribing information. Purdue Pharma L.P.

2. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2020). General principles for evaluating abuse-deterrent properties of opioid drug products: Guidance for industry. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2017). FDA approves new oral medication with abuse-deterrent properties for treatment of pain. U.S. Department of Health and Human Services.